About this episode
The rapidly growing area of regenerative medicine is promising to replace chronic therapies with cures. As the biotechnology industry gathers in San Francisco for a big week of meetings, the Alliance for Regenerative Medicine is readying to deliver its annual State of the Industry Briefing. We spoke to Edward Lanphier, president and CEO of Sangamo Biosciences and the newly elected chairman of the alliance, about the transformation of medicine that’s underway, the particular excitement among investors and industry over gene therapy, and why he’s confident payers are ready to embrace the new technology.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report
Resetting Severe Allergies at Their Cellular Source
The Bio Report
Sep 2, 202633:17pending
Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Aug 26, 202629:35pending
Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
Aug 19, 202634:19pending
How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report
Aug 12, 202638:31pending